Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | EVP AND GROUP PRESIDENT | February 27, 2026 | March 04, 2026 |
| NEVRO CORPNVRO · Entity 12422 | Director | May 21, 2018 | May 23, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 27, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 90,407 |
Reported balance
After 2026-02-27 transaction · row 1
1 source rowRow 1 · 2026-02-27 · Tax withholding · Disposed 8,577 · Balance 90,407 |
NEVRO CORP
Report date May 21, 2018 · Filed May 23, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,303 |
Reported balance
After 2018-05-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-05-21 · Grant · Acquired 3,785 · Balance 5,303 F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 21, 2018 or (ii) the next Annual Meeting following May 21, 2018, subject to the Reporting Person's continued service to the issuer. F2: Includes 3,785 RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 21, 2018 or (ii) the next Annual Meeting following May 21, 2018, subject to the Reporting Person's continued service to the issuer.
F2: Includes 3,785 RSUs.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Intersect ENT, Inc.
Report date July 24, 2019 · Filed July 26, 2019
Section 16 reporting ended · disclosed 2019-07-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.95 · Expires 2019-10-22 | Direct | 0 |
Reported balance
After 2019-07-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-07-24 · Disposition to issuer · Disposed 44,625 · Balance 0 F2: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 17, 2018 and 1/8th of the shares subject to the option vested on July 1, 2018 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.95 · Expires 2019-12-06 | Direct | 44,625 |
Reported balance
After 2019-07-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-07-24 · Grant · Acquired 44,625 · Balance 44,625 F2: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 17, 2018 and 1/8th of the shares subject to the option vested on July 1, 2018 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.06 · Expires 2019-10-22 | Direct | 0 |
Reported balance
After 2019-07-24 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-07-24 · Disposition to issuer · Disposed 150,000 · Balance 0 F4: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 21, 2015 and 1/8th of the shares subject to the option vested on July 1, 2015 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.06 · Expires 2019-12-06 | Direct | 150,000 |
Reported balance
After 2019-07-24 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-07-24 · Grant · Acquired 150,000 · Balance 150,000 F4: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 21, 2015 and 1/8th of the shares subject to the option vested on July 1, 2015 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.90 · Expires 2019-10-22 | Direct | 0 |
Reported balance
After 2019-07-24 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-07-24 · Disposition to issuer · Disposed 196,875 · Balance 0 F5: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 15, 2016 and vest in equal monthly installments over four years. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.90 · Expires 2019-12-06 | Direct | 196,875 |
Reported balance
After 2019-07-24 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-07-24 · Grant · Acquired 196,875 · Balance 196,875 F5: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 15, 2016 and vest in equal monthly installments over four years. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.05 · Expires 2019-10-22 | Direct | 0 |
Reported balance
After 2019-07-24 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-07-24 · Disposition to issuer · Disposed 45,500 · Balance 0 F6: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 18, 2017 and 1/8th of the shares subject to the option vested on July 1, 2017 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.05 · Expires 2019-12-06 | Direct | 45,500 |
Reported balance
After 2019-07-24 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2019-07-24 · Grant · Acquired 45,500 · Balance 45,500 F6: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 18, 2017 and 1/8th of the shares subject to the option vested on July 1, 2017 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.20 · Expires 2019-10-22 | Direct | 0 |
Reported balance
After 2019-07-24 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2019-07-24 · Disposition to issuer · Disposed 48,333 · Balance 0 F7: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 23, 2013, 1/48th of the shares subject to the option vested on December 30, 2013 and 1/48th of the shares subject to the option vested monthly thereafter over 47 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.20 · Expires 2019-12-06 | Direct | 48,333 |
Reported balance
After 2019-07-24 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2019-07-24 · Grant · Acquired 48,333 · Balance 48,333 F7: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 23, 2013, 1/48th of the shares subject to the option vested on December 30, 2013 and 1/48th of the shares subject to the option vested monthly thereafter over 47 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.58 · Expires 2019-10-22 | Direct | 0 |
Reported balance
After 2019-07-24 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-07-24 · Disposition to issuer · Disposed 19,688 · Balance 0 F3: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 16, 2019 and 1/8th of the shares subject to the option vested on July 1, 2019 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.58 · Expires 2019-12-06 | Direct | 19,688 |
Reported balance
After 2019-07-24 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-07-24 · Grant · Acquired 19,688 · Balance 19,688 F3: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 16, 2019 and 1/8th of the shares subject to the option vested on July 1, 2019 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. |
| Common StockSEC Table I · non-derivative | Direct | 353,183 |
Reported balance
Holding disclosure · report date 2019-07-24 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 353,183 |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 26,182 |
Reported balance
Holding disclosure · report date 2019-07-24 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 26,182 F1: Shares in the name of Lisa Damkroger Earnhardt C/F Jack L. Earnhardt UTMA/CA Until Age 25 for the benefit of Reporting Person's son. Reporting Person disclaims beneficial ownership of these shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares in the name of Lisa Damkroger Earnhardt C/F Jack L. Earnhardt UTMA/CA Until Age 25 for the benefit of Reporting Person's son. Reporting Person disclaims beneficial ownership of these shares.
F2: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 17, 2018 and 1/8th of the shares subject to the option vested on July 1, 2018 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled.
F3: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 16, 2019 and 1/8th of the shares subject to the option vested on July 1, 2019 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled.
F4: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 21, 2015 and 1/8th of the shares subject to the option vested on July 1, 2015 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019.
F5: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 15, 2016 and vest in equal monthly installments over four years. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled.
F6: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 18, 2017 and 1/8th of the shares subject to the option vested on July 1, 2017 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled.
F7: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 23, 2013, 1/48th of the shares subject to the option vested on December 30, 2013 and 1/48th of the shares subject to the option vested monthly thereafter over 47 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2026 Filed Mar 4, 2026 00:44 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 8,577 | $116.26 | $997,162.02 |
DisclosureSEC source: 0001530893-26-000004 · form4-03042026_120314.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · EVP AND GROUP PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,407 Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 111,533 | $0.00 Strike: $114.60 | $0.00 |
DisclosureSEC source: 0001530893-26-000002 · form4-02262026_110237.xml · derivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · EVP AND GROUP PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,533 Underlying: Common Shares · 111,533 shares Expires 2036-02-23 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 37,177 on February 24, 2027, 37,178 on February 24, 2028, and 37,178 on February 24, 2029. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 27,056 | $0.00 | $0.00 |
DisclosureSEC source: 0001530893-26-000002 · form4-02262026_110237.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · EVP AND GROUP PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,984 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| March 07, 2025 Filed Mar 7, 2025 23:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 200 | $0.00 Strike: $80.98 | $0.00 |
DisclosureSEC source: 0001415889-25-007453 · form4-03072025_110313.xml · derivative · entry 6 Earnhardt Lisa D · CIK 0001530893 · EVP AND GROUP PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 200 shares Expires 2029-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 07, 2025 Filed Mar 7, 2025 23:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $136.65 | $27,329.00 |
DisclosureSEC source: 0001415889-25-007453 · form4-03072025_110313.xml · nonDerivative · entry 4 Earnhardt Lisa D · CIK 0001530893 · EVP AND GROUP PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,928 Read SEC document |
| March 07, 2025 Filed Mar 7, 2025 23:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 200 | $80.98 | $16,196.00 |
DisclosureSEC source: 0001415889-25-007453 · form4-03072025_110313.xml · nonDerivative · entry 3 Earnhardt Lisa D · CIK 0001530893 · EVP AND GROUP PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2025 Filed Mar 7, 2025 23:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 91,167 | $0.00 Strike: $80.98 | $0.00 |
DisclosureSEC source: 0001415889-25-007453 · form4-03072025_110313.xml · derivative · entry 5 Earnhardt Lisa D · CIK 0001530893 · EVP AND GROUP PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200 Underlying: Common shares · 91,167 shares Expires 2029-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 06, 2025 Filed Mar 7, 2025 23:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 91,167 | $133.82 | $12,199,967.94 |
DisclosureSEC source: 0001415889-25-007453 · form4-03072025_110313.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · EVP AND GROUP PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,928 Read SEC document |
| March 06, 2025 Filed Mar 7, 2025 23:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 91,167 | $80.98 | $7,382,703.66 |
DisclosureSEC source: 0001415889-25-007453 · form4-03072025_110313.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · EVP AND GROUP PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,095 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 00:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 8,322 | $135.87 | $1,130,710.14 |
DisclosureSEC source: 0001415889-25-006743 · form4-03052025_120339.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · EVP AND GROUP PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,928 Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 22:58 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 69,977 | $0.00 Strike: $135.42 | $0.00 |
DisclosureSEC source: 0001415889-25-005886 · form4-02272025_100253.xml · derivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,977 Underlying: Common Shares · 69,977 shares Expires 2035-02-24 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 23,325 on February 25, 2026, 23,326 on February 25, 2027, and 23,326 on February 25, 2028. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 22:58 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 18,788 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005886 · form4-02272025_100253.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,250 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| May 07, 2024 Filed May 8, 2024 21:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 22,852 | $106.25 | $2,428,118.69 |
DisclosureSEC source: 0001415889-24-012624 · form4-05082024_090550.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,462 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.08 to $106.39, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 23:50 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 694 | $118.50 | $82,239.00 |
DisclosureSEC source: 0001415889-24-006405 · form4-03042024_110302.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,314 Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 23:50 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 7,669 | $120.05 | $920,663.45 |
DisclosureSEC source: 0001415889-24-006405 · form4-03042024_110302.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,008 Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 64,787 | $0.00 Strike: $116.98 | $0.00 |
DisclosureSEC source: 0001415889-24-005098 · form4-02232024_100219.xml · derivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,787 Underlying: Common Shares · 64,787 shares Expires 2034-02-20 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 21,595 on February 21, 2025, 21,596 on February 21, 2026, and 21,596 on February 21, 2027. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 17,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-005098 · form4-02232024_100219.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,677 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 00:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 943 | $100.70 | $94,960.10 |
DisclosureSEC source: 0001415889-23-003901 · form4-03032023_120327.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,437 Read SEC document |
| February 28, 2023 Filed Mar 3, 2023 00:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 7,631 | $99.77 | $761,344.87 |
DisclosureSEC source: 0001415889-23-003901 · form4-03032023_120327.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,380 Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 23:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 62,527 | $0.00 Strike: $106.24 | $0.00 |
DisclosureSEC source: 0001415889-23-003050 · form4-02222023_110253.xml · derivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,527 Underlying: Common Shares · 62,527 shares Expires 2033-02-16 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 20,842 on February 17, 2024, 20,842 on February 17, 2025, and 20,843 on February 17, 2026. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 23:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 15,855 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-003050 · form4-02222023_110253.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,011 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 21:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 19,592 | $112.71 | $2,208,214.32 |
DisclosureSEC source: 0001415889-22-006538 · form4-06142022_020653.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,156 Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 21:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,882 | $112.71 | $324,830.22 |
DisclosureSEC source: 0001415889-22-006538 · form4-06142022_020653.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,748 Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 00:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 943 | $118.15 | $111,415.73 |
DisclosureSEC source: 0001415889-22-002190 · form4-03022022_040309.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,630 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 5,168 | $122.41 | $632,614.88 |
DisclosureSEC source: 0001415889-22-002190 · form4-03022022_040309.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,573 Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 80,380 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0001415889-22-001734 · form4-02232022_050212.xml · derivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,380 Underlying: Common Shares · 80,380 shares Expires 2032-02-17 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 26,793 on February 18, 2023, 26,793 on February 18, 2024, and 26,794 on February 18, 2025. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 17,247 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001734 · form4-02232022_050212.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,741 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,881 | $109.05 | $314,173.05 |
DisclosureSEC source: 0001415889-21-002958 · form4-06112021_020627.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,494 Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 00:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 943 | $120.61 | $113,735.23 |
DisclosureSEC source: 0001415889-21-001201 · form4-03022021_040300.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,375 Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 00:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,621 | $121.58 | $318,661.18 |
DisclosureSEC source: 0001415889-21-001201 · form4-03022021_040300.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,318 Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:45 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 71,070 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000890 · form4-02232021_030231.xml · derivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,070 Underlying: Common Shares · 71,070 shares Expires 2031-02-18 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 23,690 on February 19, 2022, 23,690 on February 19, 2023, and 23,690 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:45 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 13,865 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000890 · form4-02232021_030231.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,939 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 21:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 872 | $90.84 | $79,215.97 |
DisclosureSEC source: 0001179110-20-007293 · edgar.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,074 Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 21:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,855 | $90.27 | $257,720.85 |
DisclosureSEC source: 0001179110-20-007293 · edgar.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,946 Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:36 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 114,940 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002291 · edgar.xml · derivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,940 Underlying: Common shares · 114,940 shares Expires 2030-02-20 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 38,313 on February 21, 2021, 38,313 on February 21, 2022, and 38,314 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:36 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 18,855 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002291 · edgar.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,801 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 16:55 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantStock Option (Right to buy) · Derivative | 48,333 | Not disclosed Strike: $1.20 | Not disclosed |
DisclosureSEC source: 0001562180-19-004078 · primarydocument.xml · derivative · entry 14 Earnhardt Lisa D · CIK 0001530893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,333 Underlying: Common Stock · 48,333 shares Expires 2019-12-06 F7 · kind: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 23, 2013, 1/48th of the shares subject to the option vested on December 30, 2013 and 1/48th of the shares subject to the option vested monthly thereafter over 47 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. F7 · price: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 23, 2013, 1/48th of the shares subject to the option vested on December 30, 2013 and 1/48th of the shares subject to the option vested monthly thereafter over 47 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. F7 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 23, 2013, 1/48th of the shares subject to the option vested on December 30, 2013 and 1/48th of the shares subject to the option vested monthly thereafter over 47 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 16:55 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Disposition to issuerStock Option (Right to buy) · Derivative | 48,333 | Not disclosed Strike: $1.20 | Not disclosed |
DisclosureSEC source: 0001562180-19-004078 · primarydocument.xml · derivative · entry 13 Earnhardt Lisa D · CIK 0001530893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,333 shares Expires 2019-10-22 F7 · kind: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 23, 2013, 1/48th of the shares subject to the option vested on December 30, 2013 and 1/48th of the shares subject to the option vested monthly thereafter over 47 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. F7 · price: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 23, 2013, 1/48th of the shares subject to the option vested on December 30, 2013 and 1/48th of the shares subject to the option vested monthly thereafter over 47 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. F7 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 23, 2013, 1/48th of the shares subject to the option vested on December 30, 2013 and 1/48th of the shares subject to the option vested monthly thereafter over 47 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 16:55 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantStock Option (Right to buy) · Derivative | 45,500 | Not disclosed Strike: $13.05 | Not disclosed |
DisclosureSEC source: 0001562180-19-004078 · primarydocument.xml · derivative · entry 12 Earnhardt Lisa D · CIK 0001530893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,500 Underlying: Common Stock · 45,500 shares Expires 2019-12-06 F6 · kind: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 18, 2017 and 1/8th of the shares subject to the option vested on July 1, 2017 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. F6 · price: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 18, 2017 and 1/8th of the shares subject to the option vested on July 1, 2017 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. F6 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 18, 2017 and 1/8th of the shares subject to the option vested on July 1, 2017 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 16:55 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Disposition to issuerStock Option (Right to buy) · Derivative | 45,500 | Not disclosed Strike: $13.05 | Not disclosed |
DisclosureSEC source: 0001562180-19-004078 · primarydocument.xml · derivative · entry 11 Earnhardt Lisa D · CIK 0001530893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,500 shares Expires 2019-10-22 F6 · kind: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 18, 2017 and 1/8th of the shares subject to the option vested on July 1, 2017 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. F6 · price: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 18, 2017 and 1/8th of the shares subject to the option vested on July 1, 2017 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. F6 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 18, 2017 and 1/8th of the shares subject to the option vested on July 1, 2017 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 16:55 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantStock Option (Right to buy) · Derivative | 196,875 | Not disclosed Strike: $18.90 | Not disclosed |
DisclosureSEC source: 0001562180-19-004078 · primarydocument.xml · derivative · entry 10 Earnhardt Lisa D · CIK 0001530893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,875 Underlying: Common Stock · 196,875 shares Expires 2019-12-06 F5 · kind: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 15, 2016 and vest in equal monthly installments over four years. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. F5 · price: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 15, 2016 and vest in equal monthly installments over four years. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. F5 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 15, 2016 and vest in equal monthly installments over four years. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 16:55 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Disposition to issuerStock Option (Right to buy) · Derivative | 196,875 | Not disclosed Strike: $18.90 | Not disclosed |
DisclosureSEC source: 0001562180-19-004078 · primarydocument.xml · derivative · entry 9 Earnhardt Lisa D · CIK 0001530893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 196,875 shares Expires 2019-10-22 F5 · kind: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 15, 2016 and vest in equal monthly installments over four years. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. F5 · price: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 15, 2016 and vest in equal monthly installments over four years. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. F5 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 15, 2016 and vest in equal monthly installments over four years. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 16:55 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantStock Option (Right to buy) · Derivative | 150,000 | Not disclosed Strike: $21.06 | Not disclosed |
DisclosureSEC source: 0001562180-19-004078 · primarydocument.xml · derivative · entry 8 Earnhardt Lisa D · CIK 0001530893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2019-12-06 F4 · kind: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 21, 2015 and 1/8th of the shares subject to the option vested on July 1, 2015 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. F4 · price: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 21, 2015 and 1/8th of the shares subject to the option vested on July 1, 2015 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. F4 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 21, 2015 and 1/8th of the shares subject to the option vested on July 1, 2015 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 16:55 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Disposition to issuerStock Option (Right to buy) · Derivative | 150,000 | Not disclosed Strike: $21.06 | Not disclosed |
DisclosureSEC source: 0001562180-19-004078 · primarydocument.xml · derivative · entry 7 Earnhardt Lisa D · CIK 0001530893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2019-10-22 F4 · kind: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 21, 2015 and 1/8th of the shares subject to the option vested on July 1, 2015 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. F4 · price: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 21, 2015 and 1/8th of the shares subject to the option vested on July 1, 2015 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. F4 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 21, 2015 and 1/8th of the shares subject to the option vested on July 1, 2015 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 16:55 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantStock Option (right to buy) · Derivative | 19,688 | Not disclosed Strike: $28.58 | Not disclosed |
DisclosureSEC source: 0001562180-19-004078 · primarydocument.xml · derivative · entry 6 Earnhardt Lisa D · CIK 0001530893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,688 Underlying: Common Stock · 19,688 shares Expires 2019-12-06 F3 · kind: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 16, 2019 and 1/8th of the shares subject to the option vested on July 1, 2019 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. F3 · price: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 16, 2019 and 1/8th of the shares subject to the option vested on July 1, 2019 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. F3 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 16, 2019 and 1/8th of the shares subject to the option vested on July 1, 2019 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 16:55 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Disposition to issuerStock Option (right to buy) · Derivative | 19,688 | Not disclosed Strike: $28.58 | Not disclosed |
DisclosureSEC source: 0001562180-19-004078 · primarydocument.xml · derivative · entry 5 Earnhardt Lisa D · CIK 0001530893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,688 shares Expires 2019-10-22 F3 · kind: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 16, 2019 and 1/8th of the shares subject to the option vested on July 1, 2019 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. F3 · price: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 16, 2019 and 1/8th of the shares subject to the option vested on July 1, 2019 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. F3 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 16, 2019 and 1/8th of the shares subject to the option vested on July 1, 2019 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 16:55 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantStock Option (Right to buy) · Derivative | 44,625 | Not disclosed Strike: $33.95 | Not disclosed |
DisclosureSEC source: 0001562180-19-004078 · primarydocument.xml · derivative · entry 4 Earnhardt Lisa D · CIK 0001530893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,625 Underlying: Common Stock · 44,625 shares Expires 2019-12-06 F2 · kind: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 17, 2018 and 1/8th of the shares subject to the option vested on July 1, 2018 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. F2 · price: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 17, 2018 and 1/8th of the shares subject to the option vested on July 1, 2018 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. F2 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 17, 2018 and 1/8th of the shares subject to the option vested on July 1, 2018 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 16:55 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Disposition to issuerStock Option (Right to buy) · Derivative | 44,625 | Not disclosed Strike: $33.95 | Not disclosed |
DisclosureSEC source: 0001562180-19-004078 · primarydocument.xml · derivative · entry 3 Earnhardt Lisa D · CIK 0001530893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,625 shares Expires 2019-10-22 F2 · kind: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 17, 2018 and 1/8th of the shares subject to the option vested on July 1, 2018 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. F2 · price: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 17, 2018 and 1/8th of the shares subject to the option vested on July 1, 2018 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. F2 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 17, 2018 and 1/8th of the shares subject to the option vested on July 1, 2018 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 21:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 91,367 | $0.00 Strike: $80.98 | $0.00 |
DisclosureSEC source: 0001179110-19-007549 · edgar.xml · derivative · entry 3 Earnhardt Lisa D · CIK 0001530893 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,367 Underlying: Common shares · 91,367 shares Expires 2029-06-09 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 30,455 on June 10, 2020, 30,456 on June 10, 2021, and 30,456 on June 10, 2022. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 21:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 39,515 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-007549 · edgar.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,946 F2 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with the award vesting on June 10, 2022. The award includes the right to have shares withheld for tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.